<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00935142</url>
  </required_header>
  <id_info>
    <org_study_id>[18F]VM4-037</org_study_id>
    <secondary_id>CaIX</secondary_id>
    <nct_id>NCT00935142</nct_id>
  </id_info>
  <brief_title>Non-invasive Imaging With [18F]VM4-037</brief_title>
  <acronym>[18F]VM4-037</acronym>
  <official_title>Non Invasive Imaging of [18F]VM4-037 With Positron-Emission-Tomography (PET): A Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the toxicity of the hypoxia PET-tracer
      [18F]-VM4-037 in cancer patients in two dose-steps:

        -  Step 1 (3-6 patients): a single dose of maximum 8 mCi (296 MBq) dose of [18F]VM4-037 via
           a bolus IV injection.

        -  Step 2 (3-6 patients): a single dose of maximum 12 mCi (444 MBq) dose of [18F]VM4-037
           via a bolus IV injection
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity (CTCAE 3.0)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Image Quality</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with circulating biomarkers of hypoxia</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with [18F]-FDG on PET scans</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Stage 4 Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]VM4-037</intervention_name>
    <description>Bolus IV injection of [18F]VM4-037</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological confirmed solid tumour, primary or secondary stage IV and/
             or tumours with no curative treatment options

          -  WHO performance status 0 to 1

          -  Normal white blood cell count and formula

          -  Normal platelet count

          -  No anaemia requiring blood transfusion or erythropoietin

          -  Adequate hepatic function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for the
             institution; ALT, AST, and alkaline phosphatase ≤ 2.5 x ULN for the institution)

          -  Calculated Creatinin clearance at least 60 ml/min

          -  No administration of Fluor-18 in the previous 24 hours

          -  The patient is capable of complying with study procedures

          -  18 years or older

        Exclusion Criteria:

          -  Only visible tumor sites in the upper abdomen (because the uptake of VM4-037 in the
             liver, stomach and the kidneys would interfere with image quality of the tumor)

          -  Known hypersensitivity for sulfonamides

          -  Recent (&lt; 3 months) myocardial infarction

          -  Uncontrolled infectious disease

          -  Less than 18 years old

          -  Pregnancy

          -  No concurrent anti-cancer agents or radiotherapy allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Lambin, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV cancer with no treatment options</keyword>
  <keyword>non-curative</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

